Veeva Systems's Days Sales Outstanding for the
three
months ended in Apr. 2026 was 98.3.
Veeva Systems's Days Inventory for the
three
months ended in Apr. 2026 was 0.
Veeva Systems's Days Payable for the
three
months ended in Apr. 2026 was 16.63.
Therefore, Veeva Systems's Cash Conversion Cycle (CCC) for the
three
months ended in Apr. 2026 was 81.67.
Veeva Systems (BSP:V2EE34) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Veeva Systems Cash Conversion Cycle Related Terms
Veeva Systems Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Veeva Systems's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:V2EE34 vs BTSG, TEM, HQY: Cash Conversion Cycle Comparison
For the Health Information Services subindustry, Veeva Systems's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Veeva Systems Cash Conversion Cycle vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Veeva Systems's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Veeva Systems's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Veeva Systems's Cash Conversion Cycle for the fiscal year that ended in Jan. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Veeva Systems (BSP:V2EE34) has a Cash Conversion Cycle of 81.67 as of Apr. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Veeva Systems and its competitors.
Is Veeva Systems' Cash Conversion Cycle too high?
Veeva Systems' current Cash Conversion Cycle is 81.67. The Healthcare Providers & Services industry median Cash Conversion Cycle is 17.91. Veeva Systems' value of 81.67 is 356% above this industry median. Overall, Veeva Systems has a GF Score™ of 97/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Veeva Systems' Cash Conversion Cycle compare to BTSG and TEM?
Veeva Systems' Cash Conversion Cycle of 81.67 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Conversion Cycle is 17.91. Veeva Systems' value of 81.67 is 356% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Healthcare Providers & Services company?
The median Cash Conversion Cycle among Healthcare Providers & Services companies is 17.91, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Veeva Systems's current Cash Conversion Cycle of 81.67 is 356% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Veeva Systems and its competitors. For the Healthcare Providers & Services industry, the median Cash Conversion Cycle is 17.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veeva Systems's current Cash Conversion Cycle is 81.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veeva Systems stock overvalued right now?
Based on GuruFocus' analysis, Veeva Systems (BSP:V2EE34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$48.58, compared to a current price of R$32.73 — trading 32.6% below its estimated fair value. The current Cash Conversion Cycle is 81.67 and 356% above the Healthcare Providers & Services industry median of 17.91. Veeva Systems' overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Veeva Systems (BSP:V2EE34), the current Cash Conversion Cycle is 81.67 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Veeva Systems (BSP:V2EE34) Overvalued in 2026?
Based on GuruFocus' analysis, Veeva Systems stock appears to be undervalued.
The current stock price of R$32.73 is trading 32.6% below its estimated GF Value™ of R$48.58.
GuruFocus considers Veeva Systems to be Significantly Undervalued.
Key valuation signals for BSP:V2EE34:
Cash Conversion Cycle: 81.67
GF Value™: R$48.58 vs. price of R$32.73 (32.6% below fair value)
Industry Position: 356% above the Healthcare Providers & Services median
No single metric tells the full story. See the BSP:V2EE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
97GF Score
Get the complete analysis for BSP:V2EE34
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:V2EE34 has been successfully added to your 
